{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T17:15:50Z","timestamp":1790270150959,"version":"4.1.0"},"reference-count":49,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T00:00:00Z","timestamp":1747180800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Pharmacol Toxicol"],"DOI":"10.1186\/s40360-025-00925-z","type":"journal-article","created":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T09:59:39Z","timestamp":1747216779000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Prevalence and clinical significance of potential drug-drug interactions of antimicrobials in Intensive Care Unit patients: a retrospective study"],"prefix":"10.1186","volume":"26","author":[{"given":"Shanshan","family":"Xu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhihui","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jie","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiawei","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,5,14]]},"reference":[{"key":"925_CR1","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1002\/phar.1395","volume":"34","author":"EV Uijtendaal","year":"2014","unstructured":"Uijtendaal EV, van Harssel LL, Hugenholtz GW, et al. Analysis of potential drug-drug interactions in medical intensive care unit patients. Pharmacotherapy 2014;34:213\u201319.","journal-title":"Pharmacotherapy"},{"key":"925_CR2","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1007\/s00228-014-1745-3","volume":"70","author":"J Holm","year":"2014","unstructured":"Holm J, Eiermann B, Eliasson E, et al. A limited number of prescribed drugs account for the great majority of drug-drug interactions. Eur J Clin Pharmacol 2014;70:1375\u201383.","journal-title":"Eur J Clin Pharmacol"},{"key":"925_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00228-017-2357-5","volume":"74","author":"WY Zheng","year":"2018","unstructured":"Zheng WY, Richardson LC, Li L, et al. Drug-drug interactions and their harmful effects in hospitalised patients: a systematic review and meta-analysis. Eur J Clin Pharmacol 2018;74:15\u201327.","journal-title":"Eur J Clin Pharmacol"},{"issue":"17","key":"925_CR4","doi-asserted-by":"publisher","first-page":"1840","DOI":"10.2146\/ajhp060641","volume":"64","author":"A Rivkin","year":"2007","unstructured":"Rivkin A.Admissions to a medical intensive care unit related to adverse drug reactions. Am J Health Syst Pharm. 2007;64(17):1840\u201343.","journal-title":"Am J Health Syst Pharm"},{"key":"925_CR5","doi-asserted-by":"publisher","first-page":"1035","DOI":"10.1007\/s40264-019-00829-y","volume":"42","author":"MG Fitzmaurice","year":"2019","unstructured":"Fitzmaurice MG, Wong A, Akerberg H, et al. Evaluation of potential drug-drug interactions in adults in the intensive care unit: a systematic review and meta-analysis. Drug Saf 2019;42:1035\u201344.","journal-title":"Drug Saf"},{"key":"925_CR6","doi-asserted-by":"publisher","first-page":"e877","DOI":"10.1097\/CCM.0000000000002533","volume":"45","author":"SL Kane-Gill","year":"2017","unstructured":"Kane-Gill SL, Dasta JF, Buckley MS, et al. Clinical Practice Guideline: safe Medication Use in the ICU. Crit Care Med 2017;45:e877\u2013e915.","journal-title":"Crit Care Med"},{"issue":"3","key":"925_CR7","doi-asserted-by":"publisher","first-page":"266","DOI":"10.18433\/J35C7Z","volume":"12","author":"CS Moura","year":"2009","unstructured":"Moura CS, Acurcio FA, Belo NO.Drug-drug interactions associated with length of stay and cost of hospitalization. J Pharm Pharm Sci. 2009;12(3):266\u201372.","journal-title":"J Pharm Pharm Sci"},{"key":"925_CR8","first-page":"87","volume":"23","author":"H A\u015fc\u0131","year":"2016","unstructured":"A\u015fc\u0131 H, S\u00f6nmez Y, Sayg\u0131n M, et al. Investigation of the presence of potential drug-drug interactions in the adult intensive care unit: a retrospective study. S\u00fcleyman Demirel \u00dcniversitesi Tip Fak\u00fcltesi Dergisi 2016;23:87\u201396.","journal-title":"S\u00fcleyman Demirel \u00dcniversitesi Tip Fak\u00fcltesi Dergisi"},{"key":"925_CR9","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1002\/pds.5415","volume":"31","author":"C Leal Rodr\u00edguez","year":"2022","unstructured":"Leal Rodr\u00edguez C, S. K-HB, et al. Drug interactions in hospital prescriptions in Denmark: prevalence and associations with adverse outcomes. Pharmacoepidemiol Drug Saf 2022;31:632\u201342.","journal-title":"Pharmacoepidemiol Drug Saf"},{"issue":"4","key":"925_CR10","first-page":"643","volume":"37","author":"F Shakeel","year":"2018","unstructured":"Shakeel F, Khan JA, Aamir M.Relationship of factors affecting clinically important drug interactions and their significance in surgical intensive care units in Pakistan. Lat Am J Pharm. 2018;37(4):643\u201350.","journal-title":"Lat Am J Pharm"},{"key":"925_CR11","first-page":"526","volume":"53","author":"SS Hasan","year":"2012","unstructured":"Hasan SS, Lim KN, Anwar M, et al. Impact of pharmacists\u2019 intervention on identification and management of drug-drug interactions in an intensive care setting. Singap Med J 2012;53:526\u201331.","journal-title":"Singap Med J"},{"key":"925_CR12","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s40264-024-01412-w","volume":"47","author":"L Li","year":"2024","unstructured":"Li L, Baker J, Quirk R, et al. Drug-Drug Interactions and Actual Harm to Hospitalized Patients: a Multicentre Study Examining the Prevalence Pre- and Post-Electronic Medication System Implementation. Drug Saf 2024;47:557\u201369.","journal-title":"Drug Saf"},{"key":"925_CR13","doi-asserted-by":"publisher","first-page":"1223","DOI":"10.1016\/j.mcna.2006.06.008","volume":"90","author":"MP Pai","year":"2006","unstructured":"Pai MP, Momary KM, Rodvold KA. Antibiotic drug interactions. Med Clin North Am. 2006;90:1223\u201355.","journal-title":"Med Clin North Am"},{"key":"925_CR14","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1001\/jama.2020.2717","volume":"323","author":"JL Vincent","year":"2020","unstructured":"Vincent JL, Sakr Y, Singer M, et al. Prevalence and Outcomes of Infection among Patients in Intensive Care Units in 2017. Jama 2020;323:1478\u201387.","journal-title":"Jama"},{"issue":"4","key":"925_CR15","doi-asserted-by":"publisher","first-page":"257","DOI":"10.4103\/2279-042X.192461","volume":"5","author":"R Kheshti","year":"2016","unstructured":"Kheshti R, Aalipour M, Namazi S.A comparison of five common drug-drug interaction software programs regarding accuracy and comprehensiveness. J Res Pharm Pract. 2016;5(4):257\u201363.","journal-title":"J Res Pharm Pract"},{"key":"925_CR16","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1186\/1472-6947-7-7","volume":"7","author":"KA Clauson","year":"2007","unstructured":"Clauson KA, Marsh WA, Polen HH, et al. Clinical decision support tools: analysis of online drug information databases. BMC Med Inform Decis Mak. 2007;7:7.","journal-title":"BMC Med Inform Decis Mak"},{"issue":"4","key":"925_CR17","doi-asserted-by":"publisher","first-page":"674","DOI":"10.1345\/aph.1H423","volume":"41","author":"JR Horn","year":"2007","unstructured":"Horn JR, Hansten PD, Chan L-N.Proposal for a new tool to evaluate drug interaction cases. Ann Pharmacother. 2007;41(4):674\u201380.","journal-title":"Ann Pharmacother"},{"issue":"4","key":"925_CR18","doi-asserted-by":"publisher","first-page":"c179","DOI":"10.1159\/000339789","volume":"120","author":"A Khwaja","year":"2012","unstructured":"Khwaja A.KDIGO clinical practice guidelines for acute kidney injury. Nephron Clin Pract. 2012;120(4):c179\u2013c184.","journal-title":"Nephron Clin Pract"},{"key":"925_CR19","doi-asserted-by":"crossref","unstructured":"American Diabetes Association Professional Practice Committee. Glycemic Goals and Hypoglycemia: standards of Care in Diabetes-2024. Diabetes Care. 2024;47(Suppl 1).","DOI":"10.2337\/dc24-S006"},{"key":"925_CR20","doi-asserted-by":"publisher","first-page":"1874","DOI":"10.1097\/HJH.0000000000003480","volume":"41","author":"G Mancia","year":"2023","unstructured":"Mancia G, Kreutz R, Brunstr\u00f6m M, et al. ESH Guidelines for the management of arterial hypertension The Task Force for the management of arterial hypertension of the European Society of Hypertension: endorsed by the International Society of Hypertension (ISH) and the European Renal Association (ERA). J Hypertens 2023;41:1874\u20132071.","journal-title":"J Hypertens"},{"issue":"40","key":"925_CR21","doi-asserted-by":"publisher","first-page":"3997","DOI":"10.1093\/eurheartj\/ehac262","volume":"43","author":"K Zeppenfeld","year":"2022","unstructured":"Zeppenfeld K, Tfelt-Hansen J, de Riva M, et al. ESC Scientific Document Group. 2022 ESC Guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. Eur Heart J. 2022;43(40):3997\u20134126.","journal-title":"Eur Heart J"},{"key":"925_CR22","doi-asserted-by":"publisher","first-page":"982","DOI":"10.1016\/j.jacc.2008.12.014","volume":"53","author":"PM Rautaharju","year":"2009","unstructured":"Rautaharju PM, Surawicz B, Gettes LS, et al. AHA\/ACCF\/HRS recommendations for the standardization and interpretation of the electrocardiogram. Part iv: the ST segment, T and U waves, and the QT interval. A scientific statement from the American Heart Association Electrocardiography and Arrhythmias Co. J Am Coll Cardiol. 2009;53:982\u201391.","journal-title":"J Am Coll Cardiol"},{"issue":"3","key":"925_CR23","doi-asserted-by":"publisher","first-page":"276","DOI":"10.11613\/BM.2012.031","volume":"22","author":"ML McHugh","year":"2012","unstructured":"McHugh ML.Interrater reliability: the kappa statistic. Biochem Med (Zagreb). 2012;22(3):276\u201382.","journal-title":"Biochem Med (Zagreb)"},{"issue":"2","key":"925_CR24","doi-asserted-by":"publisher","first-page":"222","DOI":"10.1590\/S0104-11692009000200013","volume":"17","author":"REF Lima","year":"2009","unstructured":"Lima REF, De Bortoli Cassiani SH.Potential drug interactions in intensive care patients at a teaching hospital. Rev Lat Am Enfermagem. 2009;17(2):222\u201327.","journal-title":"Rev Lat Am Enfermagem"},{"key":"925_CR25","doi-asserted-by":"publisher","first-page":"1052","DOI":"10.1007\/s11096-016-0340-3","volume":"38","author":"M Ismail","year":"2016","unstructured":"Ismail M, Khan F, Noor S, et al. Potential drug-drug interactions in medical intensive care unit of a tertiary care hospital in Pakistan. Int J Clin Pharm 2016;38:1052\u201356.","journal-title":"Int J Clin Pharm"},{"issue":"1","key":"925_CR26","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1590\/S1807-59322011000100003","volume":"66","author":"AMM Reis","year":"2011","unstructured":"Reis AMM, Cassiani SHDB.Prevalence of potential drug interactions in patients in an intensive care unit of a university hospital in Brazil. Clinics (Sao Paulo). 2011;66(1):9\u201315.","journal-title":"Clinics (Sao Paulo)"},{"key":"925_CR27","doi-asserted-by":"publisher","first-page":"97","DOI":"10.1016\/j.jcrc.2016.09.014","volume":"38","author":"D Vanham","year":"2017","unstructured":"Vanham D, Spinewine A, Hantson P, et al. Drug-drug interactions in the intensive care unit: do they really matter? J Crit Care. 2017;38:97\u2013103.","journal-title":"J Crit Care"},{"issue":"22","key":"925_CR28","first-page":"7108","volume":"25","author":"M Jafarova Demirkapu","year":"2021","unstructured":"Jafarova Demirkapu M, Pinar Kara S.Potential drug-drug interactions in University Hospital Medical Intensive Care Unit patients in Turkey. Eur Rev Med Pharmacol Sci. 2021;25(22):7108\u201314.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"925_CR29","first-page":"e44961","volume":"15","author":"DM Sulaiman","year":"2023","unstructured":"Sulaiman DM, Shaba SS, Almufty HB, et al. Screening the Drug-Drug Interactions Between antimicrobials and Other Prescribed Medications Using Google Bard and Lexicomp\u00ae Online\u2122 Database. Cureus 2023;15:e44961.","journal-title":"Cureus"},{"key":"925_CR30","first-page":"1291","volume":"26","author":"K Tecen-Yucel","year":"2020","unstructured":"Tecen-Yucel K, Bayraktar-Ekincioglu A, Yildirim T, et al. Assessment of Clinically Relevant Drug Interactions by Online Programs in Renal Transplant Recipients. J Manag Care Spec Pharm 2020;26:1291\u201396.","journal-title":"J Manag Care Spec Pharm"},{"key":"925_CR31","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1200\/JOP.18.00483","volume":"15","author":"BG Rogala","year":"2019","unstructured":"Rogala BG, Charpentier MM, Nguyen MK, et al. Oral anticancer therapy: management of drug interactions. J Oncol Pract 2019;15:81\u201390.","journal-title":"J Oncol Pract"},{"key":"925_CR32","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1111\/bcp.13425","volume":"84","author":"GE Benoist","year":"2018","unstructured":"Benoist GE, van Oort IM, Smeenk S, et al. Drug-drug interaction potential in men treated with enzalutamide: mind the gap. Br J Clin Pharmacol 2018;84:122\u201329.","journal-title":"Br J Clin Pharmacol"},{"key":"925_CR33","doi-asserted-by":"publisher","first-page":"17","DOI":"10.21037\/atm-22-5463","volume":"11","author":"Y Liu","year":"2023","unstructured":"Liu Y, Wang J, Gong H, et al. Prevalence and associated factors of drug-drug interactions in elderly outpatients in a tertiary care hospital: a cross-sectional study based on three databases. Ann Transl Med 2023;11:17.","journal-title":"Ann Transl Med"},{"key":"925_CR34","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1007\/s11096-021-01346-8","volume":"44","author":"A Abbas","year":"2022","unstructured":"Abbas A, Al-Shaibi S, Sankaralingam S, Awaisu A, et al. Determination of potential drug-drug interactions in prescription orders dispensed in a community pharmacy setting using Micromedex\u00ae and Lexicomp\u00ae: a retrospective observational study. Int J Clin Pharm 2022;44:348\u201356.","journal-title":"Int J Clin Pharm"},{"key":"925_CR35","doi-asserted-by":"publisher","first-page":"1178","DOI":"10.1177\/10781552221104814","volume":"29","author":"MY Bektay","year":"2023","unstructured":"Bektay MY, Seker Z, Eke HK, et al. Comparison of different decision support software programs in perspective of potential drug-drug interactions in the oncology clinic. J Oncol Pharm Pract 2023;29:1178\u201386.","journal-title":"J Oncol Pharm Pract"},{"issue":"3","key":"925_CR36","doi-asserted-by":"publisher","first-page":"e217","DOI":"10.1200\/JOP.2016.016212","volume":"13","author":"JB Bossaer","year":"2017","unstructured":"Bossaer JB, Thomas CM.Drug Interaction Database Sensitivity With Oral Antineoplastics: an Exploratory Analysis. J Oncol Pract. 2017;13(3):e217\u201322.","journal-title":"J Oncol Pract"},{"key":"925_CR37","doi-asserted-by":"publisher","first-page":"111","DOI":"10.1159\/000518439","volume":"107","author":"B Roca","year":"2022","unstructured":"Roca B, Roca M. Assessment of Drug Interactions with Online Electronic Checkers in Multi-Pathological Patients. Pharmacology. 2022;107:111\u201315.","journal-title":"Pharmacology"},{"key":"925_CR38","first-page":"9396","volume":"27","author":"HY Jiang","year":"2023","unstructured":"Jiang HY, Yu LY, Wang X, et al. Prevalence of potential drug-drug interactions among intensive care unit patients receiving linezolid: a cross-sectional study. Eur Rev Med Pharmacol Sci 2023;27:9396\u2013400.","journal-title":"Eur Rev Med Pharmacol Sci"},{"key":"925_CR39","first-page":"3):243","volume":"28","author":"MJ Armahizer","year":"2013","unstructured":"Armahizer MJ, Seybert AL, Smithburger PL, Kane-Gill SL. Drug-drug interactions contributing to QT prolongation in cardiac intensive care units. J Crit Care. 2013;28:3):243\u20139.","journal-title":"J Crit Care"},{"key":"925_CR40","doi-asserted-by":"publisher","first-page":"6):893","DOI":"10.1093\/jamia\/ocaa034","volume":"27","author":"H Edrees","year":"2020","unstructured":"Edrees H, Amato MG, Wong A, et al. High-priority drug-drug interaction clinical decision support overrides in a newly implemented commercial computerized provider order-entry system: override appropriateness and adverse drug events. J Am Med Inform Assoc. 2020;27:6):893\u2013900.","journal-title":"J Am Med Inform Assoc"},{"issue":"6","key":"925_CR41","doi-asserted-by":"publisher","first-page":"625","DOI":"10.1007\/s00228-010-0987-y","volume":"67","author":"AM Reis","year":"2011","unstructured":"Reis AM, Cassiani SH.Adverse drug events in an intensive care unit of a university hospital. Eur J Clin Pharmacol. 2011;67(6):625\u201332.","journal-title":"Eur J Clin Pharmacol"},{"key":"925_CR42","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1016\/j.jcrc.2020.11.020","volume":"62","author":"T Bakker","year":"2021","unstructured":"Bakker T, Abu-Hanna A, Dongelmans DA, et al. Clinically relevant potential drug-drug interactions in intensive care patients: a large retrospective observational multicenter study. J Crit Care. 2021;62:124\u201330.","journal-title":"J Crit Care"},{"issue":"7","key":"925_CR43","doi-asserted-by":"publisher","first-page":"875","DOI":"10.1007\/s00228-017-2232-4","volume":"73","author":"N Muhi\u010d","year":"2017","unstructured":"Muhi\u010d N, Mrhar A, Brvar M.Comparative analysis of three drug-drug interaction screening systems against probable clinically relevant drug-drug interactions: a prospective cohort study. Eur J Clin Pharmacol. 2017;73(7):875\u201382.","journal-title":"Eur J Clin Pharmacol"},{"key":"925_CR44","doi-asserted-by":"publisher","first-page":"515","DOI":"10.1590\/S1807-59322006000600005","volume":"61","author":"J Cruciol-Souza","year":"2006","unstructured":"Cruciol-Souza J, Thomson JC. A pharmacoepidemiologic study of drug interactions in a Brazilian teaching hospital. Clinics. 2006;61:515\u201320.","journal-title":"Clinics"},{"key":"925_CR45","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1002\/pds.1351","volume":"16","author":"ML Becker","year":"2007","unstructured":"Becker ML, Kallewaard M, Caspers PWJ, et al. Hospitalisations and emergency department visits due to drug-drug interactions: a literature review. Pharmacoepidemiol Drug Saf. 2007;16:641\u201351.","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"925_CR46","doi-asserted-by":"crossref","unstructured":"Gago-S\u00e1nchez AI, Font P, C\u00e1rdenas M, et al. Real clinical impact of drug-drug interactions of immunosuppressants in transplant patients. Pharmacol Res Perspect. 2021;9(6).","DOI":"10.1002\/prp2.892"},{"key":"925_CR47","doi-asserted-by":"publisher","first-page":"1308260","DOI":"10.3389\/fphar.2024.1308260","volume":"15","author":"J Zhang","year":"2024","unstructured":"Zhang J, Ma D, Chen M, et al. Prevalence and clinical significance of potential drug-drug interactions among lung transplant patients. Front Pharmacol. 2024;15:1308260.","journal-title":"Front Pharmacol"},{"key":"925_CR48","doi-asserted-by":"publisher","first-page":"121071","DOI":"10.1016\/j.lfs.2022.121071","volume":"310","author":"LS Alnaim","year":"2022","unstructured":"Alnaim LS, Almalki HM, Almutairi AM, et al. The prevalence of drug-drug interactions in cancer therapy and the clinical outcomes. Life Sci. 2022;310:121071.","journal-title":"Life Sci"},{"key":"925_CR49","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1186\/s40360-022-00582-6","volume":"23","author":"H Wang","year":"2022","unstructured":"Wang H, Shi H, Wang N, et al. Prevalence of potential drug\u2009-\u2009drug interactions in the cardiothoracic intensive care unit patients in a Chinese tertiary care teaching hospital. BMC Pharmacol Toxicol 2022;23:39.","journal-title":"BMC Pharmacol Toxicol"}],"container-title":["BMC Pharmacology and Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s40360-025-00925-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s40360-025-00925-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,14]],"date-time":"2025-05-14T11:02:53Z","timestamp":1747220573000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpharmacoltoxicol.biomedcentral.com\/articles\/10.1186\/s40360-025-00925-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,14]]},"references-count":49,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["925"],"URL":"https:\/\/doi.org\/10.1186\/s40360-025-00925-z","relation":{},"ISSN":["2050-6511"],"issn-type":[{"value":"2050-6511","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,14]]},"assertion":[{"value":"5 February 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 April 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The protocols used in this retrospective study were reviewed and approved by the institutional ethics board of Beijing Tongren Hospital (TRECKY2024-106). The requirement for individual informed consent was waived by the institutional ethics board of Beijing Tongren Hospital because this study used currently existing medical records collected during the course of routine medical care and did not pose any additional risks to the patients. All patient data were anonymized prior to the analysis. All methods and experimental protocols in this study were conducted in accordance with the approved protocols and Ethics Committee\u2019s existing guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors confirm that the Principal Investigator for this paper is Shanshan Xu and that she had direct clinical responsibility for patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Principal investigator statement"}},{"value":"The authors declare that they have no competing interests.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}